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Abstract: Breast cancer is the second leading cause of cancer death in women only next to lung cancer. In 
normal cells, BRCA1 and BRCA2 (breast cancer susceptibility gene 1 and breast cancer susceptibility gene 2) 
ensure the stability of DNA and also prevent uncontrolled cell growth. Mutation of these genes is linked to the 
development of hereditary breast and ovarian cancers. Considering the lacunae of reliable and potential drugs to 
cure the life threatening breast cancer, the present study has focused on m o l e c u l a r  computational analysis to 
identify the potential compounds, derived from mangrove e c o s y s t e m , which can block the mutated gene 
(BRCA1) responsible for the breast cancer. Six compounds were tested against the carcinogenic protein. The 3D 
crystal structure of the protein was retrieved from protein data bank (PDB) and the protein binding sites of the 
test compounds were identified. The results revealed t h a t  a m o n g  s i x  c o m p o u n d s ,  t r i t e r p e n o i d ,  
s t i g m a s t e r o l  a n d  pyrethrin w e r e  found efficient in destroying the protein (BRCA1) responsible for breast 
cancer. 
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INTRODUCTION 
Breast cancer is the most common cancer in women 
worldwide. It is a type of cancer where cells in the breast 
divide and grow without normal control. The incidence of 
breast cancer has doubled during the past 30 years. Between 
50 and 75 per cent of breast cancers begin in the ducts, 10 to 
15 per cent begin in the lobules and a few begin in other 
breast tissues (Dillon et. al., 2010) According to American 
Cancer Society’s Global Cancer Facts and Figures, nearly 
1.4 million new cases of breast cancer occurred among 
women worldwide in 2008. In general, developed countries 
have higher rates than developing countries. Although factors 
that make up this difference are mysterious, lifestyle and 
reproductive factors play a major role.  
Women who carry a mutated gene of BRCA1 or BRCA2 
have an increased risk of both breast and ovarian cancers. 
Women who have a BRCA1 or BRCA2 mutation, have a 60 to 
80 per cent chance of getting breast cancer and a 15 to 60 per 
cent chance of getting ovarian cancer, both by the age of 70 
(American Cancer Society, 2009). BRCA1 (breast cancer 1, 
early onset) is a human tumor suppressor gene that produces a 
protein called breast cancer type 1 susceptibility protein. Due 
to the presence of two domains viz. Zinc finger, C3HC4 type 
(RING finger) and BRCA1 C Terminus (BRCT) domain, the 
BRCA1 protein is also known as RING finger protein 53 
(Paterson, 1998). The BRCA1 gene is located on 17q21 and 
has a total length of about 100 kb. This gene consists of 24 
exons, and the coding region starts at the middle of exon 
(Miki et. al, 1994). The gene product of BRCA1 is a 
phosphorylated protein that consists of 1863 amino acids and 
has a molecular weight of 220kDa (Ruffner and Verma., 
1997). The RING finger structure is present at the N-terminal 
region, and a binding site for Rad51 resides in the central part 
of the primary structure. Two BRCT domains, often seen in 
proteins that act as cell checkpoints or are involved in DNA 
repair, are present in the C-terminal region. The BRCT 
domains in BRCA1 can remodel chromatin and activate 
transcription (Miyake et al., 2000).  BRCA1 protein is 
localized in the nucleus (Wilson et al., 1999).  Recent studies 
have shown that small deletions, insertions, nonsense 
mutations and splicing aberrations account for 87% of all 
pathogenic mutations of the BRCA1 gene, resulting in the 
generation of BRCA1 protein (Couch and Weber, 1996). 
BRCA1 is expressed in the cells of breast and other tissues, 
where it helps to repair damaged DNA, or destroys cells if 
DNA cannot be repaired. If BRCA1 itself is damaged, 
damaged DNA is not repaired properly and this increases risks 
for cancers (Friedenson, 2007). The protein encoded by the 
BRCA1 gene combines with other tumor suppressors, DNA 
damage sensors, and signal transducers to form a large multi-
subunit protein complex known as the BRCA1-associated 
genome surveillance complex (Wang et. al., 2000). The 
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BRCA1 protein associates with RNA polymerase II, and 
through the C-terminal domain, also interacts with histone 
deacetylase complexes. Thus, this protein plays a role in 
transcription, DNA repair of double-stranded breaks 
ubiquitination (Friedenson, 2007), transcriptional regulation 
as well as other functions (Starita and Parvin., 2003). Women 
with defects in either the BRCA1 or BRCA2 gene have a 
greater than 80 per cent chance of developing breast cancer. 
The majority of breast cancer cases are due to BRCA1 and 
BRCA2 (Thakur and Phadke, 2005). Since, the vulnerability of 
BRCA1 is more than BRCA2 gene (Ford et al., 1998), in the 
present study only BRCA1 protein was tested against 6 
chemical inhibitors derived from coastal mangrove ecosystem 
through bio-computational analysis.  
MATERIALS AND METHODS 
Protein Structure 
The 3-D crystal structure of the targeted breast cancer 
protein BRCA1 (ID: 3PXB) was retrieved from the protein 
data bank (PDB) (www.rcsb.org/pdb). Structural and active 
site studies of the protein were done by using CASTP 
(Computed Atlas of Surface Topography of Proteins) and 
pymol molecular visualization software. According to 
Lipinski’s rule of five, a compound having not more than 5 
hydrogen bond donors (OH an NH groups), not more than 10 
hydrogen bond acceptors (notably N and O), molecular weight 
under 500 g/mol, partition coefficient log P of less than 5 and 
rotatable bonds of less than 10 is taken as drug molecules and 
docking procedure is carried out (Lipinski et al., 2001).   
Chemicals screened 
Six chemicals namely t r i t e r p e n o i d ,  s t i g m a s t e r o l ,  
r u b r o l i d e n ,  t r i c i n  a n d  N - m e t h y l f l i n d e r s i n e  
identified from the coastal mangrove ecosystems (Kathiresasn 
and  Qasim, 2005)  were screened against the breast 
cancer protein (BRCA1).  
Amino acid binding site 
The pubchem database was used for retrieving the 
phytochemical molecules. The selected chemical structures 
were generated from SMILES notation (Simplified Molecular 
Input Line Entry Specification) by using the Chemsketch 
Software (www.acdlabs.com). The predicted binding sites, 
based on the binding energy, and amino acids make up of the 
binding cavity. The predicted ligand binding site residues are 
listed in Table 1.
 
Table 1.  Breast cancer protein BRCA1 binding site 
Amino acids in the binding pocket  Binding site amino acids in the structural unit  
ALA1669, ARG1670, ARG1835 
ALA1693, ALA1752, ASN1678 
ALA1789, ARG1649 
Alpha Helix 
Coil 
Beta strand 
 
Docking methods  
The molecular docking was performed using Argus Lab, 
widely distributed public domain molecular docking software. 
The inhibitor and target protein were geometrically optimized 
and docked using docking engine Argus dock. 
RESULTS 
Six chemicals derived from mangrove ecosystem were 
docked with protein responsible for breast cancer (BRCA1). 
The docked ligand molecules were selected based on docking 
energy and good interaction with the active site residues and 
the results are shown in Table 2. Of the 6 ligand molecules, 3 
showed the activation energy of greater than 10 kcal/mol and 
the remaining 3 molecules exhibited the values less than 10 
kcal/mol. The highest activation energy (- 13.0471 Kcal/mol) 
was found with triterpenoid (Figure 1) f o l l o w e d  b y  
s t i g m a s t e r o l ,  p y r e t h r i n ,  N - m e t h y l f l i n d e r s i n  
a n d  r u b r o l i d e n .  W h i l e ,  the lowest activation energy of 
6.2275 Kcal/mol was found with tricin. From the in silico 
docking results, it is quite evident that mangrove-derived 
compounds have the great potential against anti tumor activity 
of breast cancer protein BRCA1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. 3D structure of triterpenoid 
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Table 2. Docking results of mangrove derived compounds against BRCA1 protein 
 
 
Compound 
Name 
Pubchem ID Compound structure Molecular Weight 
[g/mol] 
Hydrogen  donor/ 
acceptor 
Docking 
Energy 
Level 
Triterpenoid CID: 9804218  458.6041[g/mol] (2,3) -13.0691 
kcal/mol 
stigmasterol 
 
CID: 5280794  
 
 
 
 
 
 
 
 
269.082[g/mol] (1,1) -11.5995 
kcal/mol 
pyrethrin  
CID:6433155 
 
 
 
 
 
 
 372.454 [g/mol] 
 
 
(0,5) -10.3912 k 
cal/mol 
N-
Methylflindersin
e 
CID: 72819  241.2851[g/mol] 
C24H18N2O4 
(0,2) -9.06183 k 
cal/mol 
rubrolide 
 
 
 
 
 
CID 5472704  472.51196 
 
(2,4) -7.8583 k 
cal/mol 
tricin CID: 5281702 
CH3
O
OH
O
CH3
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OH
330.288[g/mol] (3,7) -7.31076 k 
cal/mol 
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DISCUSSION 
Recent studies have shown that small deletions, insertions, 
nonsense mutations and splicing aberrations account for 87% 
of all pathogenic mutations of the BRCA1 gene, resulted in the 
generation of truncated BRCA1 protein (Couch and Weber, 
1996).  Molecular docking is a key tool in structural 
molecular biology and computer-assisted drug design. 
Mangrove-derived compounds such as triterpenoid and 
stigmasterol have already been studied for computation 
selection against sterol carrying protein, AeSCP-2 (Senthil 
and Kathiresan, 2011) and cervical viral oncoprotein, HPV16 
E6 (Senthil and Kathiresan, 2011). The present s tudy  a l so  
proved that  the  coastal mangrove-derived compounds are 
capable of blocking the oncoprotein, responsible for breast 
cancer.  
CONCLUSION 
Mangroves are rich in phenolic compounds of medicinal 
value.  These   compounds   are   ecofriendly,   safer   
and cheaper fo r  appl icat ion. Identification of BRCA1 will 
facilitate early diagnosis of breast and ovarian cancer 
susceptibility in some individuals as well as a better 
understanding of breast cancer biology. The results obtained 
from this study would be useful in both understanding the 
inhibitory mode of mangrove- derived compounds as well as 
in rapidly and accurately predicting the activities of newly 
designed inhibitors on the basis of docking scores. Here we 
concluded that these compounds derived from mangrove  
ecosystem (triterpenoid, s t i g m a s t e r o l  a n d  p y r e t h r i n ) 
could be novel chemical inhibitors for BRCA1 protein 
preventing the uncontrolled cell division. Further research is 
needed for refinement to enrich the activity of the ligands 
and destroying mechanism of the breast cancer protein, 
especially in the animal model system, and also to determine 
the dosage of safety levels, in order to explore this promising 
avenue for breast cancer control and to ensure the healthy state 
of women. 
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